D. Paul Harkin

5.3k citations

64 papers · 3.7k indexed · h-index 35

Impact in

Oncology top 2%
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
Cancer Research top 2%
- Cancer Genomics and Diagnostics

Papers in

Genetics 27
- BRCA gene mutations in cancer 25
Oncology 20
- Cancer-related Molecular Pathways 6

Co-authors: Paul B. Mullan Richard D. Kennedy Jennifer E. Quinn Kienan I. Savage Patrick G. Johnston Julia J. Gorski Niamh E. Buckley Daniel A. Haber
Journals: Cancer Research (8 papers)Oncogene (6 papers)Nucleic Acids Research (4 papers)Journal of Clinical Oncology (4 papers)Biochemical Society Transactions (3 papers)
Partner nations: United Kingdom Australia United States

In The Last Decade

D. Paul Harkin

63 papers receiving 3.6k citations

Peers

Countries citing papers authored by D. Paul Harkin

Since Specialization

Citations

This map shows the geographic impact of D. Paul Harkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Paul Harkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Paul Harkin more than expected).

Fields of papers citing papers by D. Paul Harkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Paul Harkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Paul Harkin. The network helps show where D. Paul Harkin may publish in the future.

Co-authors

The 25 scholars most cited alongside D. Paul Harkin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. Paul Harkin Line = papers co-authored together D. Paul Harkin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment BMJ Open ·马钟, Melanie Morris, Rebecca Gallagher, 西尔维奥·埃雷拉, Рахимжанов Канат Хисматович, D. Paul Harkin, Ewa Wielogórska, Christopher T. Elliott, Kienan I. Savage, Stuart McIntosh	2018	3
2	Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer Laboratory Investigation ·Peter Bankhead, José A. Fernández, Darragh G. McArt, David P. Boyle, Gerald Li, Maurice B. Loughrey, Gareth Irwin, D. Paul Harkin, Jacqueline A. James, Stephen McQuaid, Manuel Salto‐Tellez, Peter W. Hamilton	2017	77
3	Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) Journal of Clinical Oncology ·Donna Niedzwiecki, Wendy L. Frankel, Alan P. Venook, Xing Ye, Paula N. Friedman, Richard M. Goldberg, Robert J. Mayer, Thomas A. Colacchio, Jude M. Mulligan, Timothy S. Davison, Eamonn O’Brien, Peter Kerr, Patrick G. Johnston, Richard D. Kennedy, D. Paul Harkin, Richard L. Schilsky, Monica M. Bertagnolli, Robert S. Warren, Federico Innocenti	2016	35
4	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer JNCI Journal of the National Cancer Institute ·Eileen E. Parkes, Steven M. Walker, Laura E. Taggart, Nuala McCabe, Laura A. Knight, Richard D. Wilkinson, Karen D. McCloskey, Niamh E. Buckley, Kienan I. Savage, Manuel Salto‐Tellez, Stephen McQuaid, Mary T. Harte, Paul B. Mullan, D. Paul Harkin, Richard D. Kennedy	2016	341
5	Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM Cancer Research ·Nuala McCabe, Masoumeh Kaboli Farshchi, Steven M. Walker, David Gonda, Jie Li, Katarina Wikström, Kienan I. Savage, Karl T. Butterworth, Clark C. Chen, D. Paul Harkin, Kevin M. Prise, Richard D. Kennedy	2015	64
6	BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability Cancer Research ·Kienan I. Savage, Kyle B. Matchett, Rika Kawaharada, K Cooper, Gareth Irwin, Julia J. Gorski, 哲夫岡西, Sedighe Morakabati, Joy N. Kavanagh, Angelina F. Madden, David K. Bailly, Lorenzo Manti, Simon S. McDade, Ben Ho Park, Kevin M. Prise, Stuart McIntosh, Manuel Salto‐Tellez, Derek J. Richard, Christopher T. Elliott, D. Paul Harkin	2014	8
7	Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability Molecular Cell ·Kienan I. Savage, Julia J. Gorski, Rika Kawaharada, Gareth Irwin, Lorenzo Manti, David K. Bailly, Andrea Pellagatti, Natalia Lukashchuk, Dennis J. McCance, W. Glenn McCluggage, Giuseppe Schettino, Manuel Salto‐Tellez, Jacqueline Boultwood, Derek J. Richard, Simon S. McDade, D. Paul Harkin	2014	9
8	NF-κB is a critical mediator of BRCA1-induced chemoresistance Oncogene ·Mary T. Harte, Julia J. Gorski, Kienan I. Savage, Zhi Hua Song, Rika Kawaharada, Paul Burn, Cheryl McFarlane, Paul B. Mullan, Richard D. Kennedy, Neil D. Perkins, D. Paul Harkin	2013	44
9	The ΔNp63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer Cancer Research ·Niamh E. Buckley, G. Socha, Karin Jirström, Elaine W. Kay, Nyree Crawford, Anthony O’Grady, Katherine M. Sheehan, Ruosu Zhang, Ching‐Wei Wang, Dennis J. McCance, Patrick G. Johnston, Richard D. Kennedy, D. Paul Harkin, Paul B. Mullan	2011	34
10	PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer The Journal of Pathology ·Zheyu Du, Kienan I. Savage, Jaine K. Blayney, Kholada Sa’diyah, Kathy Gately, Keith M. Kerr, Michael Sheaff, Ken Arthur, Derek J. Richard, Peter W. Hamilton, Jacqueline A. James, Kenneth J. O’Byrne, D. Paul Harkin, Jennifer E. Quinn, Dean A. Fennell	2011	29
11	BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer Gynecologic Oncology ·Judith Carser, Jennifer E. Quinn, Caroline O. Michie, Eamonn O’Brien, W. Glenn McCluggage, Perry Maxwell, Kholada Sa’diyah, T F Lioe, Alistair Williams, Richard D. Kennedy, Charlie Gourley, D. Paul Harkin	2011	52
12	T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells Oncogene ·Keara L. Redmond, Nyree Crawford, Hannah Farmer, Zenobia D’Costa, Lee Chang Ro, Niamh E. Buckley, Richard D. Kennedy, Patrick G. Johnston, D. Paul Harkin, Paul B. Mullan	2010	60
13	BRCA1 and implications for response to chemotherapy in ovarian cancer Gynecologic Oncology ·Jennifer E. Quinn, Judith Carser, Colin R. James, Richard D. Kennedy, D. Paul Harkin	2009	67
14	Generation of a non-small cell lung cancer transcriptome microarray BMC Medical Genomics ·Anton Baryshnikov, Gavin R. Oliver, Vadim Farztdinov, Richard D. Kennedy, Jude M. Mulligan, Vivi Riskiyani, Susan Farragher, John K. Field, Patrick G. Johnston, D. Paul Harkin, Vitali Proutski, Karl Mulligan	2008	18
15	BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage–Inducible Gene Cancer Research ·Richard D. Kennedy, Julia J. Gorski, Jennifer E. Quinn, Gail E. Stewart, Colin R. James, Miguel Marin-Rodero, Karl Mulligan, Ethan Emberley, T F Lioe, Patrick J. Morrison, Paul B. Mullan, George Reid, Patrick G. Johnston, Peter H. Watson, D. Paul Harkin	2005	71
16	The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-γ-mediated apoptosis Oncogene ·Paul B. Mullan, Alison M. Hosey, Niamh E. Buckley, Jennifer E. Quinn, Richard D. Kennedy, Patrick G. Johnston, D. Paul Harkin	2005	46
17	BRCA1 regulates the interferon gamma-mediated apoptotic response. Clinical Cancer Research ·Paul B. Mullan, Heather N. Andrews, Hassan Rayaz, Jennifer E. Quinn, Richard D. Kennedy, Patrick Johnston, D. Paul Harkin	2003	2
18	BRCA1 : mechanisms of inactivation and implications for management of patients The Lancet ·Richard D. Kennedy, Jennifer E. Quinn, Patrick G. Johnston, D. Paul Harkin	2002	88
19	BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents Oncogene ·Paul B. Mullan, Jennifer E. Quinn, Paula M. Gilmore, 옥윤석, Heather N. Andrews, Ming Sun, Nuala McCabe, Sarah McKenna, Evan Pellegrini, Young‐Han Song, Shyamala Maheswaran, Edison Liu, Daniel A. Haber, Patrick G. Johnston, D. Paul Harkin	2001	127
20	Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1 Cell ·D. Paul Harkin, James Bean, David B. Miklos, Young‐Han Song, Siti Sailah, Christoph Englert, Fred C. Christians, Leif W. Ellisen, Shyamala Maheswaran, Jonathan D. Oliner, Daniel A. Haber	1999	480

About D. Paul Harkin

D. Paul Harkin is a scholar working on Genetics, Oncology, Molecular Biology, Cancer Research and Reproductive Medicine, having authored 64 papers that have together received 3.7k indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (25 papers), CRISPR and Genetic Engineering (20 papers), DNA Repair Mechanisms (17 papers), Gene expression and cancer classification (8 papers), Cancer Genomics and Diagnostics (7 papers), Cancer-related Molecular Pathways (6 papers), Genomics and Chromatin Dynamics (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). The work is most often cited by research in Oncology (1.5k citations), Cancer Research (737 citations), Molecular Biology (2.6k citations), Genetics (892 citations) and Reproductive Medicine (215 citations). D. Paul Harkin has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include Paul B. Mullan, Richard D. Kennedy, Jennifer E. Quinn, Kienan I. Savage, Patrick G. Johnston, Julia J. Gorski, Niamh E. Buckley, Daniel A. Haber, Shyamala Maheswaran and Young‐Han Song. Their work appears in journals such as Cancer Research, Oncogene, Nucleic Acids Research, Journal of Clinical Oncology and Biochemical Society Transactions.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact